Table 1 Baseline characteristics of the participants across weight change categories at the baseline and after 3-year follow-up: the Tehran Lipid and Glucose Study (TLGS), Iran, 1999–2018
Weight change categories | Lost > 5% | Lost 3% to 5% | Stable (± 3%) | Gained 3% to 5% | Gained > 5% | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number of participants (Men) | 533 (210) | 418 (186) | 2285 (1051) | 731 (321) | 1469 (627) | 5436 (2395) | ||||||
Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow- up | |
Continuous variables, Mean ± SD | ||||||||||||
Age (year) | 51.9 ± 12.4 | 55.3 ± 12.5 | 50.3 ± 12.3 | 53.6 ± 12.4 | 48.9 ± 11.9 | 52.1 ± 12.0 | 47.2 ± 11.9 | 50.4 ± 11.8 | 44.4 ± 11.4 | 47.9 ± 11.4 | 47.9 ± 12.1 | 51.2 ± 12.1 |
BMI (kg/m2) | 29.1 ± 4.8 | 26.7 ± 4.5 | 28.5 ± 4.7 | 27.6 ± 4.5 | 27.9 ± 4.1 | 28.1 ± 4.2 | 27.3 ± 4.4 | 28.5 ± 4.6 | 26.5 ± 4.5 | 29.0 ± 4.9 | 27.6 ± 4.4 | 28.3 ± 4.5 |
SBP (mmHg) | 127.6 ± 21.2 | 120.8 ± 21.7 | 125.6 ± 20.8 | 121.8 ± 20.3 | 123.9 ± 20.3 | 121.8 ± 19.8 | 120.8 ± 18.7 | 120.8 ± 20.7 | 117.3 ± 17.9 | 118.9 ± 19.3 | 122.2 ± 19.9 | 120.8 ± 20.0 |
DBP (mmHg) | 80.7 ± 11.5 | 75.1 ± 11.4 | 79.6 ± 11.4 | 75.4 ± 10.6 | 79.6 ± 11.0 | 76.7 ± 10.7 | 78.5 ± 10.8 | 76.5 ± 10.8 | 77.1 ± 10.3 | 76.5 ± 10.5 | 78.9 ± 11.0 | 76.4 ± 10.7 |
FPG (mmol/L) | 6.3 ± 2.5 | 6.4 ± 3.2 | 6.1 ± 2.4 | 6.1 ± 2.6 | 5.7 ± 2.0 | 5.8 ± 2.0 | 5.4 ± 1.6 | 5.5 ± 1.4 | 5.3 ± 1.6 | 5.4 ± 1.3 | 5.6 ± 2.0 | 5.7 ± 2.0 |
Total cholesterol (mmol/L) | 5.9 ± 1.3 | 5.2 ± 1.1 | 5.7 ± 1.2 | 5.1 ± 1.0 | 5.7 ± 1.2 | 5.2 ± 1.1 | 5.6 ± 1.2 | 5.2 ± 1.0 | 5.4 ± 1.1 | 5.2 ± 1.1 | 5.6 ± 1.2 | 5.2 ± 1.1 |
Categorical variables, number (%) | ||||||||||||
Educational level, years | ||||||||||||
≤ 6 | 280(52.5) | 277(52.0) | 197(47.1) | 199(47.6) | 1054(46.1) | 1021(44.7) | 294(40.2) | 294(40.2) | 546(37.2) | 531(36.1) | 2371(43.6) | 2322(42.7) |
6–12 | 202(37.9) | 206(38.6) | 187(44.7) | 180(43.1) | 973(42.6) | 999(43.7) | 360(49.2) | 353(48.3) | 737(50.2) | 741(50.4) | 2459(45.2) | 2479(45.6) |
 > 12 | 51(9.6) | 50(9.4) | 34(8.1) | 39(9.3) | 258(11.3) | 265(11.6) | 77(10.5) | 84(11.5) | 186(12.7) | 197(13.4) | 606(11.1) | 635(11.7) |
Current smoking | 50(9.4) | 49(9.2) | 65(15.6) | 58(13.9) | 269(11.8) | 272(11.9) | 102(14.0) | 92(12.6) | 209(14.2) | 194(13.2) | 695(12.8) | 665(12.2) |
History of CVD, yes | 46(8.6) | 73(13.7) | 26(6.2) | 37(8.9) | 134(5.9) | 202(8.8) | 43(5.9) | 57(7.8) | 64(4.4) | 102(6.9) | 313(5.8) | 471(8.7) |
Diabetes mellitus, yes | 119(22.3) | 125(23.5) | 75(17.9) | 81(19.4) | 281(12.3) | 337(14.7) | 47(6.4) | 73(10.0) | 81(5.5) | 121(8.2) | 603(11.1) | 737(13.6) |
Hypertension, yes | 203(38.1) | 157(29.5) | 134(32.1) | 122(29.2) | 691(30.2) | 618(27.0) | 165(22.6) | 177(24.2) | 295(20.1) | 319(21.7) | 1488(27.4) | 1393(25.6) |
Hypercholesterolemia, yes | 380(71.3) | 266(49.9) | 288(68.9) | 221(52.9) | 1461(63.9) | 1159(50.7) | 457(62.5) | 367(50.2) | 780(53.1) | 687(46.8) | 3366(61.9) | 2700(49.7) |
Glucose-lowering drugs use, yes | 61(11.4) | 71(13.3) | 37(8.9) | 54(12.9) | 134(5.9) | 204(8.9) | 28(3.8) | 37(5.1) | 45(3.1) | 72(4.9) | 305(5.6) | 438(8.1) |
Anti-hypertensive drugs use, yes | 79(14.8) | 87(16.3) | 55(13.2) | 58(13.9) | 244(10.7) | 275(12.0) | 59(8.1) | 88(12.0) | 122(8.3) | 132(9.0) | 559(10.3) | 640(11.8) |
Lipid-lowering drugs use, yes | 34(6.4) | 32(6.0) | 25(6.0) | 36(8.6) | 113(4.9) | 130(5.7) | 33(4.5) | 30(4.1) | 40(2.7) | 60(4.1) | 245(4.5) | 288(5.3) |
All-cause mortality events (number) | 108 | 58 | 260 | 68 | 135 | 629 | ||||||
CV mortality events (number) | 52 | 24 | 104 | 19 | 48 | 247 | ||||||
Cancer mortality events (number) | 17 | 18 | 46 | 17 | 28 | 126 | ||||||